WILMINGTON, Del.--(BUSINESS WIRE)--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI ...
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
In a Breztri commercial that launched a year ago, a man using the AstraZeneca COPD inhaler was able to participate in hiking and other outdoor activities via an RV road trip. In this year’s spot, a ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
AstraZeneca (NASDAQ:AZN) has initiated a Phase 3 study to evaluate the use of inhaled triple-combination therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BREZTRI AEROSPHERE TM (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the ...
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...
After AstraZeneca’s fast-growing respiratory biologic Fasenra failed to move the needle in a COPD trial, hopes were directed to its three-in-one inhaler Breztri. But the potential challenger to ...
With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.
Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies WILMINGTON, Del.--(BUSINESS WIRE)-- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback